

CV Date	30/03/2022
----------------	------------

Part A. PERSONAL INFORMATION

First Name *	TERESA
Family Name *	ALONSO GORDOA

A.1. Current position

Job Title	Facultativo Especialista de Área Oncología Médica		
Starting date	2014		
Institution	Hospital Universitario Ramón y Cajal		
Department / Centre			
Country		Phone Number	
Keywords	Clinical medicine		

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2013 - 2013	Facultativo Especialista de Área / Hospital Universitario Infanta Cristina
2009 - 2013	Médico Interno Residente / Hospital Clínico San Carlos

A.3. Education

Degree/Master/PhD	University / Country	Year
Título de Experto en Inmunooncología	Universidad de Navarra	2018
Máster en Oncología Molecular, Bases Moleculares del Cáncer	Centro Nacional Investigaciones Oncológicas / Spain	2017
Programa Oficial de Doctorado en Ciencias Biomédicas	Universidad Complutense de Madrid	2010
Licenciado en Medicina y Cirugía	Universidad de Navarra	2008

A.4. General quality indicators of scientific production

Citas recibidas (Google Scholar) desde 2017:

Citaciones 1303

Índice h 18

Índice i10 29

Part B. CV SUMMARY

Teresa Alonso Gordoia is a medical oncologist at the Medical Oncology Department of the Ramón y Cajal University Hospital in Madrid. She is specialized in the care of patients with genitourinary, germ cell and endocrine tumors. In addition, she is a member of the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Genitourinary Oncology

(SOGUG), the Germ Cell Group (GG) and the Spanish Group of Neuroendocrine Tumors (GETNE). She participates actively in research projects and clinical trials with international impact. She is currently the principal investigator of different phase I-III clinical trials, all of them focused in the treatment of patients with genitourinary and endocrine tumors. In addition, she continues her training in molecular oncology with the completion of the Master in Molecular Oncology: Molecular bases of cancer and the Expert Title in Immunooncology from the University of Navarre. She is a member of the honorary faculty of the University of Alcalá and a reviewer of indexed international journals. She has presented numerous communications in national and international congresses and has participated in the publication of scientific articles in national and international journals. She is currently under the PhD program with the title "New biomarkers for kidney cancer classification in clinical practice" in the University of Alcalá.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Alfonso Cortes; Jose Luis Casado; Federico Longo; et al;. 2022. Limited T-cell response to mRNA SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments *European Journal of Cancer*.
- 2 **Scientific paper.** Maria San Roman Gil; Javier Pozas; Diana Rosero Rodriguez; et al;. 2022. Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies *Cancer Treatment Reviews*. 105.
- 3 **Scientific paper.** Marta Araujo Castro; Eider Pascual Corrales; Javier Molina Cerrillo; Nicolás Moreno Mata; Teresa Alonso Gordo. 2022. Bronchial Carcinoids: From Molecular Background to Treatment Approach *Cancers (Basel)*. 14-3, pp.520.
- 4 **Scientific paper.** Alejandra Bernardini; Marta Dueñas; Maria Cruz Martin Soberon; et al;. 2022. Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer *Cancers (Basel)*. 14-2, pp.378.
- 5 **Scientific paper.** Pablo Alvarez Ballesteros; Jesus Chamorro; Maria San Roman Gil; et al;. 2021. Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma *Cancers (Basel)*. 13-23, pp.5981.
- 6 **Scientific paper.** Alvaro Pinto; Oscar Reig; Clara Iglesias; et al;. 2021. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study *Clinical Genitourinary Cancer*. 20-1, pp.25-34.
- 7 **Scientific paper.** Marta Araujo Castro; Lia Nattero Chavez; Alberto Martinez Lorca; Javier Molina Cerrillo; Teresa Alonso Gordo; Eider Pascual Corrales. 2021. Special situations in pheochromocytomas and paragangliomas: pregnancy, metastatic disease, and cyanotic congenital heart diseases *Clinical and Experimental Medicine*.
- 8 **Scientific paper.** Juan Jose Serrano Domingo; Teresa Alonso Gordo; Javier Lorca Alvaro; et al;. 2021. The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. *Therapeutic Advances In Urology*. 13.
- 9 **Scientific paper.** Marta Araujo Castro; Eider Pascual Corrales; Lia Nattero Chavez; et al;. 2021. Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: a multidisciplinary approach *Journal of Endocrinological Investigation*.
- 10 **Scientific paper.** Enrique Grande; Cristina Rodriguez Antona; Carlos López; et al;. 2021. SUNitinib and EVOfosfamide (TH-302) in systemic treatment-naïve patients with G1/G2 metastatic pancreatic neuroendocrine tumors, the GETNE-1408 trial. *The Oncologist*.

- 11 **Scientific paper.** Mohammed Dawod; Teresa Alonso Gordo; Mauro Cives; et al;. 2021. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours Current Treatment Options in Oncology. 22-73.
- 12 **Scientific paper.** Louis De Mestier; Angela Lamarca; Jorge Hernando; et al;. 2021. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. *Endocrine Related Cancer*. 28-8, pp.549-561.
- 13 **Scientific paper.** Marta Araujo Castro; Eider Pascual Corrales; Javier Molina Cerrillo; Teresa Alonso Gordo. 2021. Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance *Biomedicines*. 9-3, pp.304.
- 14 **Scientific paper.** Angela Lamarca; Mauro Cives; Louis De Mestier; Joakim Crona; Francesca Spada; Kjell Oberg; Marianne Pavel; Teresa Alonso Gordo. 2021. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3 rd-line treatment *World Journal of Gastroenterology*. 27-10, pp.976-989.
- 15 **Scientific paper.** Robert Motzer; Boris Alekseev; Sun-Young Rha; et al;. 2021. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma *New England Journal of Medicine*.
- 16 **Scientific paper.** David F McDermott; Jae-Lyun Lee; Georg A Bjarnason; et al;. 2021. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma *Journal of Clinical Oncology*.
- 17 **Scientific paper.** Pablo Maroto; Xavier García Del Muro; Claudia Valverde; et al;. 2021. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer *Urologic Oncology*. 39-2, pp.135.
- 18 **Scientific paper.** Marta Benavent; Javier Sastre; Ignacio Garcia Escobar; et al;. 2021. Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS) *Health and Quality of Life Outcomes*.
- 19 **Scientific paper.** Paula Jiménez Fonseca; Alberto Carmona Bayonas; Angela Lamarca; et al;. 2021. External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study *Neuroendocrinology*.
- 20 **Scientific paper.** Javier Molina Cerrillo; Juan Marquet Palomanes; Teresa Alonso Gordo; Javier López Jiménez; Enrique Grande. 2021. May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia *Healthcare*. 9-1, pp.78.
- 21 **Scientific paper.** Javier Torres Jiménez; Víctor Albarrán Fernández; Javier Pozas; et al;. 2021. Novel Tyrosine Kinase Targets in Urothelial Carcinoma *International Journal of Molecular Sciences*. 22-2, pp.747.
- 22 **Scientific paper.** Elettra Merola; Teresa Alonso Gordo; Panpan Zhang; et al;. 2020. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is $\geq 10\%$? *The Oncologist*.
- 23 **Scientific paper.** Guillermo De Velasco; Lucía Carril Ajuria; Félix Guerrero Ramos; et al;. 2020. A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial *Oncotarget*. 11, pp.4457-4462.
- 24 **Scientific paper.** Jorge Esteban Villarrubia; Juan José Soto Castillo; Javier Pozas; et al;. 2020. Tyrosine Kinase Receptors in Oncology *International Journal of Molecular Sciences*. 21-22.
- 25 **Scientific paper.** María Sotelo; Teresa Alonso Gordo; Pablo Gajate; et al;. 2020. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies *Clin Transl Oncol*.
- 26 **Scientific paper.** Yohann Loriot; Cora N Sternberg; Daniel Castellano; et al;. 2020. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma *European Journal of Cancer*. 138, pp.202-211.
- 27 **Scientific paper.** María San Román Gil; Javier Pozas; Javier Molina Cerrillo; et al;. 2020. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. *International Journal of Molecular Sciences*. 21-14.

- 28 **Scientific paper.** Vital Hevia; Estefanía Linares Espirós; Teresa Alonso Gordo; et al;. 2020. Renal Cell Carcinoma and COVID-19 Pandemia: Management Strategies Adapted to Current Practice Arch Esp Urol. 73-5, pp.360-366.
- 29 **Scientific paper.** Javier Molina Cerrillo; María San Román Gil; Javier Pozas; et al;. 2020. BRAF Mutated Colorectal Cancer: New Treatment Approaches.Cancers. 12-6, pp.1571.
- 30 **Scientific paper.** Javier Molina Cerrillo; Teresa Alonso Gordo; Alfredo Carrato; Enrique Grande. 2020. Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation.Oncotarget. 11-22, pp.2137-2140.
- 31 **Scientific paper.** Javier Molina Cerrillo; Teresa Alonso Gordo. 2020. Clinical surveillance in immunotherapy-treated patient.Medicina Clinica (Barc).
- 32 **Scientific paper.** Alex Teule; Teresa Alonso Gordo; Paula Jimenez Fonseca; et al;. 2020. The PALBONET trial: a phase II study of palbociclib in metastatic grade 1 and 2 pancreatic neuroendocrine tumors (GETNE-1407) The Oncologist.
- 33 **Scientific paper.** Alfonso Gómez De Liaño Lista; Nick Van Dijk; Guillermo De Velasco Oria de Rueda; et al;. 2019. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer European Urology.
- 34 **Scientific paper.** Javier Pozas; María San Román; Teresa Alonso Gordo; Miguel Pozas; Laura Caracuel; Alfredo Carrato; Javier Molina Cerrillo. 2019. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.International Journal of Molecular Sciences. 20-19.
- 35 **Scientific paper.** MP Solis Hernandez; A Fernández Del Valle; Alberto Carmona Bayonas; et al;. 2019. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).British Journal of Cancer. 121-7, pp.537-544.
- 36 **Scientific paper.** Alberto Carmona Bayonas; Paula Jiménez Fonseca; Ángela Lamarca; et al;. 2019. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.Journal of Clinical Oncology.
- 37 **Scientific paper.** Pedro Iglesias; Alberto Martínez; Pablo Gajate; Teresa Alonso; Teresa Navarro; Juan José Díez. 2019. Long-term effect of 177 LU-Dotatate on severe and refractory hypoglycemia associated with malignant insulinoma AACE Clinical Case Reports. 5-6, pp.330-333.
- 38 **Scientific paper.** Jorge Aparicio; A Sánchez Muñoz; Sebastián Ochendusko; et al;. 2019. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.Journal of Urology.
- 39 **Scientific paper.** Arantzazu Barquín García; Javier Molina Cerrillo; Pilar Garrido; Daniel García Palos; Alfredo Carrato; Teresa Alonso Gordo. 2019. New oncologic emergencies: What is there to know about immunotherapy and its potential side effects? European Journal of Internal Medicine.
- 40 **Scientific paper.** Roberto Martin Huertas; Cristina Saavedra Serrano; Cristian Perna; Ana Ferrer Gómez; Teresa Alonso Gordo. 2019. Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges.Cancer Management and Research. 11, pp.4541-4548.
- 41 **Scientific paper.** Teresa Alonso Gordo; Maria Laura García Bermejo; Enrique Grande; Pilar Garrido; Alfredo Carrato; Javier Molina Cerrillo. 2019. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".International Journal of Molecular Sciences. 20-8.
- 42 **Scientific paper.** Javier Molina Cerrillo; Enrique Grande; Teresa Alonso Gordo. 2019. Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor.The Oncologist.
- 43 **Scientific paper.** Javier Molina Cerrillo; Teresa Alonso Gordo; Pilar Garrido. 2019. Tumor-associated macrophages: "Good cop-bad cop".Cancer.
- 44 **Scientific paper.** Antonio Casado; Héctor Randal Callata; Arancha Manzano; et al;. 2018. Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.Future Oncology.

- 45 Scientific paper.** Bárbara Núñez Valdovinos; Alberto Carmona Bayonas; Paula Jiménez Fonseca; et al;. 2018. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE) *The Oncologist*. 22, pp.1-11.
- 46 Scientific paper.** Maria Joao Marques Ribeiro; Teresa Alonso Gordo; Pablo Gajate; Javier Molina; Arantza Barquin; Cristian Perna; Enrique Grande. 2018. Huge recurrent gastric neuroendocrine tumor: A case report *Autopsy and case reports journal*. Universidade de São Paulo, Hospital Universitário.
- 47 Scientific paper.** Sara Ruiz Pinto; Guillermo Pita; Miguel Martín; et al;. 2017. Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.*Breast Cancer Res Treat*.
- 48 Scientific paper.** Javier Molina Cerrillo; Teresa Alonso Gordo; Pablo Gajate; Enrique Grande. 2017. Bruto's tyrosine kinase (BTK) as a promising target in solid tumors *Cancer Treatment Reviews*.
- 49 Scientific paper.** Pablo Gajate; Olga Martínez Sáez; Teresa Alonso Gordo; Enrique Grande. 2017. Emerging use of everolimus in the treatment of neuroendocrine tumors *Cancer Management and Research*. 9, pp.1-10.
- 50 Scientific paper.** Enrique Grande; Olga Martínez Sáez; Pablo Gajate Borau; Teresa Alonso Gordo. 2017. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate.*World Journal of Clinical Oncology*. 8-2, pp.100-105.
- 51 Scientific paper.** Guillermo Crespo; Paula Jiménez Fonseca; Ana Custodio; et al;. 2017. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.*Future Oncology*. 13-7, pp.615-624.
- 52 Scientific paper.** Olga Martínez Sáez; Pablo Gajate Borau; Teresa Alonso Gordo; Javier Molina Cerrillo; Enrique Grande. 2017. Targeting HIF-2 ? in clear cell renal cell carcinoma: A promising therapeutic strategy.*Critical Reviews in Oncology/Hematology*. Elsevier. 111, pp.117-123.
- 53 Scientific paper.** Enrique Grande; Jaume Capdevila; Daniel Castellano; et al;. 2016. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).*Annals of Oncology*. 26-9, pp.1987-1993.
- 54 Scientific paper.** Javier Molina Cerrillo; Teresa Alonso Gordo; Olga Martínez Sáez; Enrique Grande. 2016. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors *The Oncologist*. 21-6, pp.701-707.
- 55 Scientific paper.** Juan José Díez; Enrique Grande; Teresa Alonso; Pedro Iglesias. 2015. Multidisciplinary approach in the diagnosis and therapy of patients with endocrine tumors.*Medicina Clinica Barcelona*. 145, pp.1-6.
- 56 Review.** Juan José Díez; Pedro Iglesias; Teresa Alonso Gordo; Enrique Grande. 2016. Improvement in the quality of patient management after the implementation of a multidisciplinary committee on endocrine tumors: An analysis of 5-year experience *Revisión de calidad asistencial: órgano de la sociedad española de calidad asistencial*. Elsevier. 32-31, pp.187-189.
- 57 Bibliographic review.** Sara Álvarez Rodríguez; Teresa Alonso Gordo; Francisco Javier Burgos Revilla. 2018. Current status of androgen deprivation therapy in hormone-sensitive prostate cancer *Arch Esp Urol*. 71-3, pp.247-257.
- 58 Bibliographic review.** Pablo Gajate; Teresa Alonso Gordo; Olga Martínez Sáez; Javier Molina Cerrillo; Enrique Grande. 2017. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.*Clin Transl Oncol*.
- 59 Bibliographic review.** Javier Molina Cerrillo; Olga Martínez Sáez; Teresa Alonso Gordo; Pedro Tirado Zambrano; Beatriz Delgado Vargas; Julie Earl; Enrique Grande. 2015. Primary sarcomatoid tumor of the bladder: a Different entity but the same approach? *Clinical Genitourinary Cancer*. 13-6, pp.493-498.
- 60 Bibliographic review.** Teresa Alonso Gordo; Juan José Díez; Pablo Reguera; Olga Martínez Sáez; Enrique Grande. 2015. An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).*Rare Cancers and Therapy*. 3, pp.13-33.

- 61 Bibliographic review.** Javier Puente Vázquez; Teresa Alonso Gordo; Jesús Moreno; Liz Poma; Eduardo Díaz Rubio; Ángel Gómez; Javier Blázquez; José Luis González Larriba. 2015. New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies. *Current Treatment Options Oncology*. 16-3, pp.337.
- 62 Bibliographic review.** Teresa Alonso Gordo; Juan José Díez; Manuel Durán; Enrique Grande. 2015. Advances in thyroid cancer treatment: latest evidence and clinical potential. *Therapeutic Advances Medical Oncology*. 7-1, pp.22-38.
- 63 Bibliographic review.** Teresa Alonso Gordo; Jaume Capdevila; Enrique Grande. 2015. GEP NETs Biotherapy in Neuroendocrine Tumors. *European Journal of Endocrinology*. 172-1, pp.R31-R46.

C.3. Research projects and contracts

- 1 Project.** Estudio observacional y retrospectivo, sobre el valor pronóstico de la expresión de PDL1 y otros marcadores moleculares angiogénicos, en pacientes con carcinoma de células renales (CCR) avanzado o metastásico tratados con fármacos antiangiogénicos en primera línea. Pfizer, S.A.. Emilio Esteban. (Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal (FIBioHRC)). 12/2019-12/2022. 300.000 €.
- 2 Project.** Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumours (NExT).. Alfredo Carrato. (Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal (FIBioHRC)). 02/09/2019-30/08/2022. 51.000 €. Team member.
- 3 Project.** The role of immunology in the prognosis and therapeutic development in localized clear cell renal cell carcinoma. Roche Farma, S.A.. Teresa Alonso Gordo. (Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal (FIBioHRC)). 10/2017-10/2019. 27.600 €.
- 4 Project.** Estudio traslacional del posible efecto sobre la modulación de macrófagos y la proliferación tumoral de telotristat en líneas celulares de tumores neuroendocrinos.. Javier Molina Cerrillo. (Instituto Madrileño de Estudios Avanzados). From 02/11/2020. 20.000 €. Team member.
- 5 Project.** Wearables en pacientes con TNE metastásico (NETFIT).. Javier Molina Cerrillo. (Grupo Español de Tumores Neuroendocrinos). From 02/03/2020. 300.000 €. Principal investigator.
- 6 Project.** Papel de la vía CXCR4/CXCL12 en pacientes con cáncer de colon BRAF mutado. Beca Fundación SEOM + 1 Súmate.. Javier Molina Cerrillo. (Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal (FIBioHRC)). From 2018. Team member.